Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Niraparib · 1 trial · 2 indications
for maintenance therapy arm
for maintenance therapy arm
| Arm | Type | Description |
|---|---|---|
| Niraparib as maintenance therapy for Endometrial Serous Carcinoma | EXPERIMENTAL | For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate. |
| Niraparib as recurrent therapy for Endometrial Carcinoma | EXPERIMENTAL | For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate. |
| Name | Type | Description |
|---|---|---|
| Niraparib | DRUG | Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression. |
Inclusion Criteria: * Women aged 18 or above * Histological confirmation of serous endometrial cancer or other types of endometrial cancer * FIGO stage III-IV * ESC Patients have received at least 6 cycles of first-line platinum containing chemotherapy after surgery and achieved CR, PR or SD; ESC p...
Niraparib is being studied as a monotherapy for the maintenance and recurrent treatment of endometrial serous carcinoma, a type of endometrial cancer. It is currently in Phase 2 clinical development for this indication. The drug is being evaluated in a controlled trial enrolling female patients aged 18 years and older.
Niraparib targets and inhibits PARP1 and PARP2, which are poly (ADP-ribose) polymerase enzymes involved in DNA repair. By inhibiting these targets, the drug is being investigated for its potential anti-cancer activity in endometrial serous carcinoma. This mechanism is the basis for its evaluation in the ongoing clinical trial.
Niraparib is being developed by Zai Lab Limited, a biopharmaceutical company listed on the stock exchange under the ticker ZLAB. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with endometrial serous carcinoma.
Niraparib is in Phase 2 clinical development for the treatment of endometrial serous carcinoma. It is an investigational drug, meaning it has not yet been approved by regulatory authorities for this indication. The ongoing trial is actively recruiting participants in China.
Niraparib is being studied in a Phase 2 clinical trial with the identifier NCT04716686. The trial is titled "Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma" and is currently recruiting participants. The study is enrolling 83 female patients with endometrial serous carcinoma in China.
Niraparib is a small molecule drug that is also known by its ChEMBL identifier CHEMBL1094636. It is being investigated as a monotherapy for endometrial serous carcinoma. The drug is not described as having any other alternative names in the clinical trial context.